Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced a clinical program comprising of trials ...

Actinium Pharmaceuticals (ATNM) announced a clinical program comprising of trials studying Actimab-A in combination with either Keytruda – ...

(RTTNews) - Actinium Pharmaceuticals, Inc. (ATNM) Tuesday has launched a clinical program evaluating Actimab-A in combination with the PD-1 inhibitors pembrolizumab - KEYTRUDA and nivolumab OPDIVO.

Actinium Pharmaceuticals (ATNM) announced that results from the clinical trial evaluating Actimab-A in combination with the chemotherapy CLAG-M ...

IT之家 3 月 20 日消息，埃隆・马斯克旗下的人工智能公司 xAI 今日为其 API 添加图像生成功能。该 API 仅支持“grok-2-image-1212”模型，该模型可根据输入的描述生成最多 10 张图像，每秒最多处理 5 ...

The firm will assess whether adding its CD33-targeted radiotherapy Actimab-A to PD-1 inhibitors will benefit patients more than PD-1 inhibitors alone.

OpenAI’s o1-pro API costs $150 (Rs. 12,900) per million input tokens and $600 (roughly Rs. 51,800) per million output tokens.

(RTTNews) - Actinium Pharmaceuticals, Inc. (ATNM) announced that results from the clinical trial evaluating Actimab-A in combination with the chemotherapy CLAG-M in patients with relapsed ...

For comparison, AI startup Black Forest Labs, with which xAI partnered last year to launch image generation on Musk’s social ...

Actinium-225 PSMA therapy is an emerging treatment for advanced prostate cancer that focuses on delivering targeted radiation ...